The current study innovatively explored the potential effects of GM-derived SCFAs on peripheral blood leukocytes, providing preliminary evidence for the protective role of SCFAs in the AF progression by regulating GPR43/NLRP3 expression and reducing IL-1β release in peripheral blood leukocytes. This evidence concerns the gene IL1B and atrial fibrillation.